MinervaX announces that it today has enrolled and dosed the last of 240 subjects in it Phase I Part B Dose-confirmation trial on its Group B Streptococcal vaccine GBS-NN.
- MinervaX provides clinical and leadership update 07/10/2021
- MinervaX announces completion of 47.4 mEUR financing 15/12/2020
- MinervaX announces investment of 4.4 mEUR 21/01/2019
- MinervaX announces results from Phase I clinical trial 05/01/2017
- Innovation Foundation Grant 19/09/2016